Lipoprotein Lipase Gene PvuII Polymorphism Serum Lipids and Risk for Coronary Artery Disease: Meta-Analysis

Our aim was to determine whether lipoprotein lipase gene PvuII polymorphism can be considered as an independent risk factor for coronary artery disease (CAD) by conducting a meta-analysis of all available published trials, including our own study. In 7 seperate studies, 3289 subjects were screened for this substitution; meta-analysis included only some of these individuals. Among the 7 studies, 6 were performed on white subjects, whereas 1 was on patients with Saudi Arabic descent.Subgroup analysis indicated that individuals with PvuII substitution does not have an increased risk for CAD. The LPL-PvuII genotype and allele frequency distributions did not differ significantly between CAD patients and healthy controls. There was no difference in the distribution of LPL-PvuII genotypes between the healthy subjects and the patients with CAD. However, no significant differences in lipid variables (triglyceride and HDL-cholesterol) were determined for the PvuII polymorphisms in the patients with CAD. No significant differences were found in serum triglyceride and HDL-cholesterol levels for LPL-PvuII genotypes when the control and CAD groups were pooled. In conclusion, LPL-Pvu II polymorphism cannot be used as independent genetic risk factor for CAD

Lipoprotein lipase gene PvuII polymorphism serum lipids and risk for coronary artery disease: Meta-analysis

Our aim was to determine whether lipoprotein lipase gene PvuII polymorphism can be considered as an independent risk factor for coronary artery disease (CAD) by conducting a meta-analysis of all available published trials, including our own study. In 7 seperate studies, 3289 subjects were screened for this substitution; meta-analysis included only some of these individuals. Among the 7 studies, 6 were performed on white subjects, whereas I was on patients with Saudi Arabic descent. Subgroup analysis indicated that individuals with PvuII substitution does not have an increased risk for CAD. The LPL-PvuII genotype and allele frequency distributions did not differ significantly between CAD patients and healthy controls. There was no difference in the distribution of LPL-PvuII genotypes between the healthy subjects and the patients with CAD. However, no significant differences in lipid variables (triglyceride and HDL-cholesterol) were determined for the PvuII polymorphisms in the patients with CAD. No significant differences were found in serum triglyceride and HDL-cholesterol levels for LPL-PvuII genotypes when the control and CAD groups were pooled. In conclusion, LPL-PvuII polymorphism cannot be used as independent genetic risk factor for CAD

Association of Resistin Gene 3'-Untranslated Region EX4-44G-->A Polymorphism with Obesity- and Insulin-Related Phenotypes in Turkish Type 2 Diabetes Patients

Resistin, an adipocyte-secreted hormone, has been associated with obesity, insulin resistance and type 2 diabetes mellitus (T2DM) in some, but not all, rodent models. In humans, the exact function of resistin is unkown. Because 3'-untranslated region (3'-UTR) single nucleotide substitutions (SNPs) have been shown to affect gene expression, we examined the EX4-44G-->A SNP in the 3'-UTR of exon 3 within the resistin gene. The objective of this study was to investigate, for the first time in a Turkish study group, whether the 3'-UTR EX4-44G-->A variation in the resistin gene influences the development of T2DM, obesity and insulin-related phenotypes. We analyzed the genotype frequencies of the EX4-44G-->A polymorphism of the resistin gene in 116 type 2 diabetic and 102 normal subjects. Serum lipids, obesity-related and insulin-related phenotypes were analyzed. No significant difference for genotypic frequencies were observed for the BseRI restriction site in type 2 diabetic patients as compared to controls. Waist-to-hip ratio, BMI, body fat and apoAI levels were found to be affected by resistin genotype. In the control group, BMI (p < 0.01), HIS (p < 0.05) and BF (p < 0.05) levels were found to be elevated, whereas HOMA β-cell index (p < 0.01) and apo AI (p < 0.05) levels were found to be decreased in GG genotype carriers. In the diabetic group, the GG genotype carriers were found to have higher BMI levels (p < 0.001), waist-to-hip ratio (p < 0.05), body fat (p < 0.01), HOMA (p < 0.001) and fasting insulin (p < 0.05), but lower HbA1c levels in comparison to GC + AA carriers. These data suggest that, in the Turkish study group, the EX4-44G-->A polymorphism of the resistin gene is associated with insulin and obesity-related phenotypes

The effects of phase II cardiac rehabilitation programme on patients undergone coronary bypass surgery

Ama?: Koroner arter cerrahisi ge?iren 52 hastaya uygulanan Faz II kardiyak rehabilitasyonun etkilerini ara?t?rmakt?r. Y?ntemler: Faz II kardiyak rehabilitasyona al?nan hastalara bu program ?ncesinde ve sonunda; dereceli y?r?me testleri, kalp-akci?er kapasite testleri, lipid profili yap?ld?. Programa uygun olarak 12 hafta boyunca haftada 3 kez 20 dakika s?reli seanslar ?eklinde, 12 kanal elektrokardiyografi kontrol?nde ko?u band?nda egzersiz antrenmanlar? yap?ld?. Hastalara d???k veya orta yo?unluklu egzersiz program? verildi. Rehabilitasyon s?resince Cleveland Clinic Chronotropic Assessment egzersiz protokolu uyguland?. Bulgular: Koroner baypas operasyonu ge?irmi? 52 hastaya uygulanan Faz II kardiyak rehabilitasyon sonunda hastalar?n efor kapasitesi, oksijen t?ketimi, anaerobik e?ik, kalp debisi ortalama de?erlerinde anlaml? artma (p?0.001), HDL-kolesterol ortalama de?erinde anlaml? artma (p?0.05) ve beden kitle indeksi (BK?), total-kolesterol, LDL-kolesterol, trigliserid ortalama rakamlar?nda anlaml? azalma (p?0,001) tespit edildi. Sonu?: Koroner arter cerrahisi ge?iren hastalarda Faz II kardiyak rehabilitasyon, ya?am kalitesi ve ikincil korunma a??s?ndan ?ok yararl? bir programd?r.Objective: To investigate the effects of phase II cardiac rehabilitation in 52 patients undergone coronary artery bypass surgery. Methods: Gradual walking tests, cardio-pulmonary capacity tests and lipid profile were administered to patients selected for phase II cardiac rehabilitation before and after the programme. Training was started on 12-channel electrocardiogram controlled running bands 3 times a week for 20 min periods for 12 weeks fitting the programme. Low or intermediate level exercise programme was applied to patients. Cleveland Clinic Chronotropic Assessment exercise protocol was used during rehabilitation. Results: As a result of phase II cardiac rehabilitation administered to 52 patients undergone coronary bypass operation, exercise capacity, oxygen consumption, anaerobic threshold, cardiac output mean values (p?0.001) and mean HDL cholesterol level (p?0.05) were found to increase, whereas body mass index, total cholesterol, LDL cholesterol and triglyceride mean levels reduced (p?0.001) significantly. Conclusion: In patients who have undergone coronary bypass surgery, phase II cardiac rehabilitation is a very useful programme in improvement of life quality and secondary prevention